Aktieanalys

Nanexa Q1 report: work in progress - ABG

ABG Sundal Collier Publicerad: 03 May 10:03

Muted quarter with work in progress
NEX-22 Ph 1 approval and start exp. by the summer
Webcast today at 12:00 CET

Relevant events during the quarter

Q1 was a quarter focused on the NEX-22 Ph 1 trial startup. The clinical trial application (CTA) for that study was submitted in Dec'23 but on 16 April Nanexa announced that the start of the study will be delayed towards the end of Q2'24. The main reason for the delay was the request of certain supplements and clarifications by the German Medicines Agency, requiring a new submission of the CTA. Following the resubmission, Nanexa received additional questions, which will be addressed thoroughly. Nanexa's management is confident about solving the issues and expects clinical data from the study by YE'24.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nanexa/Equity-research/2024/5/nanexa---q1-report-work-in-progress/

Nyheter om Nanexa

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!